Elsevier Announces New Medical Hypotheses Editor-in-Chief
– Dr. Mehar Manku Assumes Leadership of Unique Journal, Vowing to Embrace
the Journal’s Original Ethos While Implementing a Different Approach to the
Peer Review Process
Elsevier (http://www.elsevier.com) announced today that Dr.
_home/623059/description#description). In this role Dr. Manku will lead a
popular, unique journal that constitutes a bridge between cutting-edge theory
and the mainstream of medical and scientific communication. Dr. Manku
provided invaluable editorial help to Dr.
founder and first Editor-in-Chief, during a period of illness, before
becoming a member of the Editorial Board in 2004.
(Due to the length of the above URL, it may be necessary to copy and
paste this hyperlink into your Internet browser’s URL address field. Remove
the space if one exists.)
Dr. Manku stated upon his appointment, “Elsevier and I make two
commitments to ensure the long term success of this journal. First, we will
retain the ethos, heritage and unique characteristics of the journal as they
were proposed at inception. Second, we will engage a medically qualified
editorial board to get members more involved in the review system to help
ensure radical new ideas and speculations in medicine are given open-minded
consideration while ensuring scientific merit.”
Medical Hypotheses is a forum for ideas in medicine and related
biomedical sciences. It will publish interesting and important theoretical
papers that foster the diversity and debate upon which the scientific process
thrives. In the words of Dr.
Hypotheses will publish papers which describe theories, ideas which have a
great deal of observational support and some hypotheses where experimental
support is yet fragmentary”.
Dr. Manku is responsible for implementing a new form of peer review that
is unique to Medical Hypotheses submissions. Medical Hypotheses aims to give
open-minded consideration to novel, radical new ideas and speculations in
medicine which would probably be rejected by most conventional journals.
Submitted manuscripts will be reviewed by the Editor and external reviewers
to ensure their scientific merit. All reviewers will be fully aware of the
Aims and Scope of the journal and will be judging the premise, originality
and plausibility of the hypotheses submitted.
Dr. Manku has been in biomedical sciences for 35 years, developing
medicines based on fatty acids and lipids. He also spent the last 26 years as
Executive Editor and Editor-in-Chief (since 2003) of one of the leading
peer-reviewed journals in the lipid field: “Prostaglandins, Leukotrienes and
Essential Fatty Acids.” Dr. Manku is a part time Chief Scientist at Amarin
Corporation, a member of the American Oil Chemists Society and The
International Society for the Study of Fatty Acids and Lipids
The journal also plans to implement an online comment section encouraging
active participation and debate on the journal’s contents.
Elsevier is a world-leading publisher of scientific, technical and
medical information products and services. The company works in partnership
with the global science and health communities to publish more than 2,000
journals, including The Lancet (http://www.thelancet.com) and Cell
(http://www.cell.com), and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier’s online solutions include
ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com),
Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and
Nursing Consult (http://www.nursingconsult.com), which enhance the
productivity of science and health professionals, and the SciVal suite
(http://www.scival.com) and MEDai’s Pinpoint Review (http://www.medai.com),
which help research and health care institutions deliver better outcomes more
A global business headquartered in
(http://www.elsevier.com) employs 7,000 people worldwide. The company is part
of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading
publisher and information provider, which is owned jointly by Reed Elsevier
PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam),
REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
---------------------------------  (Horrobin DF, 1975 Ideas in Biomedical Science: Reasons for the foundation of Medical Hypotheses. Medical Hypotheses Volume 1, Issue 1, January-February 1975, Pages 1-2.). Tom Reller Vice President, Global Corporate Relations +1-215-239-3508 T.Reller@Elsevier.com